DWP212525

DWP212525 is a novel, highly potent, and selective small molecule inhibitor that targets both Janus kinase 3 (JAK3) and Bruton’s tyrosine kinase (BTK), with additional activity against other Tec family kinases such as ITK. It is being developed primarily for the treatment of autoimmune diseases, including rheumatoid arthritis and pemphigus vulgaris. The drug demonstrates strong selectivity for JAK3 (IC50 = 0.2 nM) and BTK (IC50 = 1.5 nM), with low affinity toward JAK1, JAK2, and EGFR[1][4][5]. Preclinical studies show that DWP212525 inhibits T- and B-cell activation by blocking key signaling pathways involved in autoantibody production, leading to reduced disease severity in animal models of pemphigus vulgaris[5]. In vivo data indicate high BTK occupancy after oral administration despite rapid plasma clearance[1]. The compound is currently undergoing phase 1 clinical trials in healthy volunteers for autoimmune indications[2][7].

Other names

DWP 212525DWP212525DWP-212525